Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Authors

John C Byrd
Amy S Ruppert
Nyla A Heerema
Alese E Halvorson
Eva Hoke
Mitchell R Smith, George Washington University
John E Godwin
Stephen Couban
Todd A Fehniger
Michael J Thirman
Martin S Tallman
Frederick R Appelbaum
Richard M Stone
Sue Robinson
Julie E Chang
Sumithra J Mandrekar
Richard A Larson

Document Type

Journal Article

Publication Date

7-24-2018

Journal

Blood Advances

Volume

2

Issue

14

Inclusive Pages

1705-1718

DOI

10.1182/bloodadvances.2017015396

Keywords

Adult; Aged; Aged, 80 and over; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Immunotherapy; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate

APA Citation

Byrd, J., Ruppert, A., Heerema, N., Halvorson, A., Hoke, E., Smith, M., Godwin, J., Couban, S., Fehniger, T., Thirman, M., Tallman, M., Appelbaum, F., Stone, R., Robinson, S., Chang, J., Mandrekar, S., & Larson, R. (2018). Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).. Blood Advances, 2 (14). http://dx.doi.org/10.1182/bloodadvances.2017015396

Peer Reviewed

1